Efficacy of Ropeginterferon Alpha 2b in Inducing Treatment Free Remission in Chronic Myeloid Leukemia - an International, Randomized Phase III Trial (ENDURE, CML-IX) of the German CML-Study Group

Burchert A, Saussele S, Michel C, Metzelder SK, Hochhaus A, Gattermann N, Crysandt M, Schafhausen P, Bormann M, Radsak MP, Guerci-Bresler A, Illmer T, Goebeler ME, Herhaus P, Teichmann LL, Franke GN, Lang F, Krause S, Moehle R, Klausmann M, Stegelmann F, Lutz C, Etienne G, Stoltefuss A, Goethert JR, Ernst T, Neubauer A, Hehlmann R, Aminossadati B, Wittenberg M, Pfirrmann M, Schade-Brittinger C, Le Coutre P, Nicolini FE (2022)


Publication Type: Conference contribution

Publication year: 2022

Journal

Publisher: AMER SOC HEMATOLOGY

City/Town: WASHINGTON

Pages Range: 1501-1503

Conference Proceedings Title: BLOOD

Event location: New Orleans, LA US

DOI: 10.1182/blood-2022-169324

Authors with CRIS profile

Involved external institutions

How to cite

APA:

Burchert, A., Saussele, S., Michel, C., Metzelder, S.K., Hochhaus, A., Gattermann, N.,... Nicolini, F.E. (2022). Efficacy of Ropeginterferon Alpha 2b in Inducing Treatment Free Remission in Chronic Myeloid Leukemia - an International, Randomized Phase III Trial (ENDURE, CML-IX) of the German CML-Study Group. In BLOOD (pp. 1501-1503). New Orleans, LA, US: WASHINGTON: AMER SOC HEMATOLOGY.

MLA:

Burchert, Andreas, et al. "Efficacy of Ropeginterferon Alpha 2b in Inducing Treatment Free Remission in Chronic Myeloid Leukemia - an International, Randomized Phase III Trial (ENDURE, CML-IX) of the German CML-Study Group." Proceedings of the 64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), New Orleans, LA WASHINGTON: AMER SOC HEMATOLOGY, 2022. 1501-1503.

BibTeX: Download